Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period

Detalhes bibliográficos
Autor(a) principal: Ravanic,Dragan B.
Data de Publicação: 2009
Outros Autores: Dejanovic,Slavica M. Djukic, Janjic,Vladimir, Jovic,Suzana D., Milovanovic,Dragan R., Jakovljevic,Vladimir, Pantovic,Vesna, Ravanic,Boris, Pantovic,Maja, Pantovic,Mihailo M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000200005
Resumo: OBJECTIVE: The aim of our study was to evaluate the effects of low doses of clozapine in flexible regime in comparison with haloperidol and chlorpromazine in long term. METHOD: The naturalistic study was prospective, active-controlled with 325 adult outpatients of both genders (140 females), with mean year age of 34.8 (range 21-57), suffering from chronic schizophrenia. The first onset of illness was at the mean of 27.9 years (range 17-38), and subjects had the mean year age of 4.1±0.5 previous relapses. The patients were allocated to receive haloperidol (105 subjects, dose range 2-15 mg), chlorpromazine (n=105, 100-400 mg) or clozapine (n=115, 75-600 mg). The scores of psychometric instruments (GWB, PANSS, CGI) were regularly assessed during 5 year period. RESULTS: The sixty-six responders were included in per-protocol analysis: 12, 10 and 16 with positive and 7, 6 and 15 with negative schizophrenic syndrome in haloperidol, chlorpromazine and clozapine group, respectively. The statistically significant differences in all psychometric scores was found, for both schizophrenic syndromes, favoring clozapine. The distribution of eighteen different types of adverse events, which we noted, were significantly different among treatment groups ( χ2=315.7, df=34, p<0.001). Clozapine was safer and had fewer adverse effects (average of 0.9 adverse events per patient) than haloperidol (2.7) and chlorpromazine (3.2). CONCLUSIONS: Clozapine, in low doses of flexible regime, in long term (five years) showed better effectiveness in chronic schizophrenics with positive and negative symptoms than typical antipsychotics.
id ABNEURO-1_200f3dcdc44681f054e133095d18afbc
oai_identifier_str oai:scielo:S0004-282X2009000200005
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year periodschizophreniaantipsychotics drugslong-term outcomesclinical practiceOBJECTIVE: The aim of our study was to evaluate the effects of low doses of clozapine in flexible regime in comparison with haloperidol and chlorpromazine in long term. METHOD: The naturalistic study was prospective, active-controlled with 325 adult outpatients of both genders (140 females), with mean year age of 34.8 (range 21-57), suffering from chronic schizophrenia. The first onset of illness was at the mean of 27.9 years (range 17-38), and subjects had the mean year age of 4.1±0.5 previous relapses. The patients were allocated to receive haloperidol (105 subjects, dose range 2-15 mg), chlorpromazine (n=105, 100-400 mg) or clozapine (n=115, 75-600 mg). The scores of psychometric instruments (GWB, PANSS, CGI) were regularly assessed during 5 year period. RESULTS: The sixty-six responders were included in per-protocol analysis: 12, 10 and 16 with positive and 7, 6 and 15 with negative schizophrenic syndrome in haloperidol, chlorpromazine and clozapine group, respectively. The statistically significant differences in all psychometric scores was found, for both schizophrenic syndromes, favoring clozapine. The distribution of eighteen different types of adverse events, which we noted, were significantly different among treatment groups ( χ2=315.7, df=34, p<0.001). Clozapine was safer and had fewer adverse effects (average of 0.9 adverse events per patient) than haloperidol (2.7) and chlorpromazine (3.2). CONCLUSIONS: Clozapine, in low doses of flexible regime, in long term (five years) showed better effectiveness in chronic schizophrenics with positive and negative symptoms than typical antipsychotics.Academia Brasileira de Neurologia - ABNEURO2009-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000200005Arquivos de Neuro-Psiquiatria v.67 n.2a 2009reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/S0004-282X2009000200005info:eu-repo/semantics/openAccessRavanic,Dragan B.Dejanovic,Slavica M. DjukicJanjic,VladimirJovic,Suzana D.Milovanovic,Dragan R.Jakovljevic,VladimirPantovic,VesnaRavanic,BorisPantovic,MajaPantovic,Mihailo M.eng2009-06-08T00:00:00Zoai:scielo:S0004-282X2009000200005Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2009-06-08T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
title Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
spellingShingle Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
Ravanic,Dragan B.
schizophrenia
antipsychotics drugs
long-term outcomes
clinical practice
title_short Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
title_full Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
title_fullStr Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
title_full_unstemmed Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
title_sort Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period
author Ravanic,Dragan B.
author_facet Ravanic,Dragan B.
Dejanovic,Slavica M. Djukic
Janjic,Vladimir
Jovic,Suzana D.
Milovanovic,Dragan R.
Jakovljevic,Vladimir
Pantovic,Vesna
Ravanic,Boris
Pantovic,Maja
Pantovic,Mihailo M.
author_role author
author2 Dejanovic,Slavica M. Djukic
Janjic,Vladimir
Jovic,Suzana D.
Milovanovic,Dragan R.
Jakovljevic,Vladimir
Pantovic,Vesna
Ravanic,Boris
Pantovic,Maja
Pantovic,Mihailo M.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ravanic,Dragan B.
Dejanovic,Slavica M. Djukic
Janjic,Vladimir
Jovic,Suzana D.
Milovanovic,Dragan R.
Jakovljevic,Vladimir
Pantovic,Vesna
Ravanic,Boris
Pantovic,Maja
Pantovic,Mihailo M.
dc.subject.por.fl_str_mv schizophrenia
antipsychotics drugs
long-term outcomes
clinical practice
topic schizophrenia
antipsychotics drugs
long-term outcomes
clinical practice
description OBJECTIVE: The aim of our study was to evaluate the effects of low doses of clozapine in flexible regime in comparison with haloperidol and chlorpromazine in long term. METHOD: The naturalistic study was prospective, active-controlled with 325 adult outpatients of both genders (140 females), with mean year age of 34.8 (range 21-57), suffering from chronic schizophrenia. The first onset of illness was at the mean of 27.9 years (range 17-38), and subjects had the mean year age of 4.1±0.5 previous relapses. The patients were allocated to receive haloperidol (105 subjects, dose range 2-15 mg), chlorpromazine (n=105, 100-400 mg) or clozapine (n=115, 75-600 mg). The scores of psychometric instruments (GWB, PANSS, CGI) were regularly assessed during 5 year period. RESULTS: The sixty-six responders were included in per-protocol analysis: 12, 10 and 16 with positive and 7, 6 and 15 with negative schizophrenic syndrome in haloperidol, chlorpromazine and clozapine group, respectively. The statistically significant differences in all psychometric scores was found, for both schizophrenic syndromes, favoring clozapine. The distribution of eighteen different types of adverse events, which we noted, were significantly different among treatment groups ( χ2=315.7, df=34, p<0.001). Clozapine was safer and had fewer adverse effects (average of 0.9 adverse events per patient) than haloperidol (2.7) and chlorpromazine (3.2). CONCLUSIONS: Clozapine, in low doses of flexible regime, in long term (five years) showed better effectiveness in chronic schizophrenics with positive and negative symptoms than typical antipsychotics.
publishDate 2009
dc.date.none.fl_str_mv 2009-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000200005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000200005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-282X2009000200005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.67 n.2a 2009
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212765533208576